Sarah, 42, felt fine after her mild Covid case. Two months later, she couldn’t walk up the stairs without gasping. Brain fog made it hard to focus at work. She wasn’t alone. Millions have faced this slow, confusing slide into long-term illness after a seemingly minor infection.
Long Covid affects up to 1 in 5 adults after infection. It can cause fatigue, brain fog, shortness of breath, and heart issues. There’s no test, no clear treatment, and no way to predict who will get it. For years, doctors could only say: rest, wait, and hope.
But here’s the twist: a simple, low-cost drug already used by millions may change that.
Metformin cuts long Covid risk by 40%.
That’s not a lab theory. It’s from a major trial of over 1,300 adults with early Covid symptoms. The drug? Metformin — a decades-old medication for type 2 diabetes. It’s safe, cheap, and widely available.
Why a diabetes drug?
Think of your cells like a factory. When a virus like SARS-CoV-2 enters, it hijacks the machinery to make more copies of itself. Metformin doesn’t attack the virus directly. Instead, it turns down the factory’s power supply. It lowers blood sugar and calms inflammation — two things that help the virus thrive.
It’s like cutting the electricity to a rogue production line.
This trial tested three drugs: metformin, fluvoxamine (an antidepressant), and ivermectin (a parasite treatment). All were studied for early outpatient use. Patients got them within days of testing positive.
The real winner? Metformin.
Patients took it within six days of symptoms. They used it for 14 days. Those who took metformin were 40% less likely to develop long Covid over the next several months.
They also had lower viral loads and fewer hospitalizations.
No other drug in the trial showed the same effect. Fluvoxamine and ivermectin did not reduce long-term symptoms or disease progression.
That’s not the full story.
Experts say this doesn’t mean everyone with Covid should start taking metformin. It was tested in a controlled setting. Most participants were overweight or had risk factors for severe Covid. We don’t yet know if it works the same in younger, healthier people.
Also, metformin can cause stomach upset, diarrhea, or nausea — especially at first. A small number of people shouldn’t take it, like those with kidney problems.
Still, the results are turning heads.
Doctors didn’t expect a diabetes drug to impact viral illness this way. But past data hinted at it. People with diabetes who took metformin had better Covid outcomes in earlier studies. This trial confirms it — and adds long-term protection to the list.
What does this mean for you?
If you get Covid, talk to your doctor about early treatment options. Metformin isn’t approved yet for this use. It’s not a substitute for vaccines or antivirals like Paxlovid. But it could become part of a broader strategy.
This doesn't mean this treatment is available yet.
The FDA hasn’t approved metformin for long Covid prevention. More research is needed to confirm who benefits most and when to use it.
The trial had limits. It only included non-hospitalized adults. It was done during earlier pandemic waves, before Omicron dominated. And while the results are strong, real-world use may differ.
Still, the potential is huge.
Metformin is generic. It costs as little as $4 a month. It’s used by over 150 million people worldwide. If confirmed, this could be a low-cost tool against a costly, disabling condition.
The next step?
Larger trials are in the works. Researchers want to test metformin in different groups — younger patients, those without risk factors, and people with repeated infections. They’ll also study how it affects specific long Covid symptoms like fatigue and memory issues.
Science moves slowly. But for the first time, we have a clear signal: early action with an old drug may prevent long-term harm.
That changes everything.
7. ENDING
Researchers are now planning broader trials to confirm metformin’s role in long Covid prevention, with results expected in the next few years. Until then, the medical community is watching closely.
